BioAuxilium is an R&D service provider for the pharmaceutical, biomedical and biotech industries, as well as academic research groups. Founded by accomplished scientists from PerkinElmer BioSignal, BioAuxilium provides a range of high-quality, customized assay development services across a number of areas including basic research, drug discovery, biologic quantification and biomarker detection on various technology platforms. BioAuxilium is based in Montréal (Québec, Canada) and has access to NEOMED Institute’s state-of-the-art laboratories and core facilities.
BioAuxilium scientists have a deep expertise in biochemical and cell-based assay design and development. Indeed, BioAuxilium founders have played a key role in the development of commercially successful assay reagents and technologies addressing multiple therapeutic targets, including AlphaLISA® kits for biomarker detection, LANCE® Ultra cAMP kit for GPCR activation, LANCE Ultra europium-labeled antibodies and ULight™-labeled peptides for kinase activity, and BRET and BRET2™ as biosensors for cAMP. BioAuxilium scientists have also provided custom assay development services, expert advice and assay troubleshooting for leading pharmaceutical companies and contract research organizations. With 50 years of experience in the detection of proteins, hormones, cytokines and even smaller analytes (cAMP, oestrogen) in biological samples as well as in the measurement of enzyme activity on various types of platforms, BioAuxilium can design and develop a robust and sensitive assay to detect and quantify your molecule of interest.
BioAuxilium’s mission is to provide the highest quality R&D services by helping our customers advance their assay development projects in a timely and cost effective manner. BioAuxilium can provide assay consultation services, design an entirely new assay or improve an existing one. Following assay development, BioAuxilium is also equipped to produce the necessary assay reagent components in order for the client to fully exploit the assay internally. Finally, BioAuxilium can help implementing the optimized assays at the client’s facility.
Custom fluorescent antibody and protein labeling service using a wide selection of labels, including fluorescent dyes for TR-FRET and TRF (DELFIA) assays, phycobiliproteins, and enzymes, along with a choice of labeling chemistries. Conjugation of your antibody or biomolecule to any AlphaLISA and AlphaScreen bead. Biotinylation of antibodies or proteins.
Biochemical, cell-based and biomarker proof-of-concept and assay development using multiple technology platforms (absorbance, fluorescence, FP, TRF (DELFIA), TR-FRET (LANCE, HTRF, LanthaScreen), luminescence, AlphaScreen, AlphaLISA).
Optimization and validation of novel or commercially available kits.
ELISA conversion to homogeneous no-wash technologies (AlphaLISA, LANCE, HTRF).
Assay design, optimization and validation for HTS.
Iterative compound testing (IC50 determination; compound ranking) for Medicinal Chemist groups.
Design, development and manufacturing of novel immunoassay kits in a variety of formats.
Custom chemical and biological reagents. Conjugation of your antibody or biomolecule to a wide range of TR-FRET, TRF (DELFIA) fluorophores or to any AlphaLISA and AlphaScreen bead. Biotinylation of antibodies or proteins.
BioAuxilium Research has not received any reviews.
BioAuxilium Research has not received any endorsements.